Kailera Therapeutics, Inc. Common Stock (KLRA) — Cash Flow-to-Debt Ratio
Kailera Therapeutics, Inc. Common Stock (KLRA) has a Cash Flow-to-Debt Ratio of -0.06x as of March 2026, meaning its operating cash flow of $-68.31 Million could theoretically repay 0% of its total liabilities ($1.06 Billion) in one year. Explore investment intensity of Kailera Therapeutics, Inc. Common Stock to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Kailera Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio (2025–2025)
Historical debt coverage capacity for Kailera Therapeutics, Inc. Common Stock across 1 annual periods. Also explore Kailera Therapeutics, Inc. Common Stock asset portfolio for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Kailera Therapeutics, Inc. Common Stock (2025–2025)
Year-by-year debt coverage analysis for Kailera Therapeutics, Inc. Common Stock. For market capitalisation and broader financial context, see Kailera Therapeutics, Inc. Common Stock (KLRA) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.11x | $-120.21 Million | $1.05 Billion | — |